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The pharmaceutical industry is an important part of our national economy. Wit
h the population aging, the pharmaceutical industry explosive growth in demand will
 follow. The investors have been focusing on the pharmaceutical industry in the capi
tal market. We make valuation analyses on the listed Corporation Guizhou Yibai pha
rmaceutical Co., Ltd and other companies in the same industry by discussing on the 
macroeconomic situation, the industry status and the financial situation of companie
s in this paper. We conduct valuation analysis on Yibai Pharmaceutical Company by
 using some usual valuation models that are being adopted among scholars, such as d
iscounted cash flow model (DCF), EVA model (EVA) and so on.use absolute valuat
ion method, relative valuation method and the industry more use. In this paper, we u
se the relative valuation method to compare Yibai Pharmaceutical Company with ot
her companines in the same industry, and also make empirical research on the scope 
and limitations of various valuation models, provideing the value reference of Yibai 
Pharmaceutical Company for investors. 
We mainly make top-down analyses in this paper: Chapter 1 introduces the rese
arch background, significance of the main contents of this thesis; In Chapter 2, we a
nalyze the new economic environment and the condition of capital market; in Chapt
er 3, we present the development of the pharmaceutical industry. Chapter 4 provides 
an introduction of the basic situation of Yibai Pharmaceutical Company; In Chapter 
5, we make comparison between Yibai and Tasly by using financial analyses; In Cha
pter 6, we conduct financial forecasting on Yibai and Tasly. In Chapter 7, we structu
re valuation models based on various business valuation theoies respectively for Yib
ai and Tasly, making comparisons between the intrinsic value and the current maket 
value of these two companines. Finally, we make our conclusions and suggestions in
 Chaper 8. 
The core-competitiveness of Guizhou Yibai pharmaceutical Co., Ltd is its sales 
team wiith high agressiveness and efficience. The company gains recognition from t
he captial market by refocusing on the sales of prescription drugs and OTC drugs an
d expanding its own product lines through continuous mergers. We conclude that the















us valuation models. That is, the share price of YIBAI is at the lower end of our valu
ation range in the premise of no major changes in main business and structure of the 
firm. Therefore, we recommend investors to buy this stock. 
The pharmaceuticals industry is an anti-cyclical industry, and its market deman
d will grow steadily with the accreleration of the aging process of population. In add
ition, this industry is driven by the resident consumption ungrade, thus having a supe
rior growth space. After selecting the industry, we need to pick the pharmaceutical fi
rms that are undervalued and having enough growth in this industry. Only after we c
onduct comprehensive analysis on the frim by using quantitative and quanlitative an
alyses and comparing its intrinsic value with market value, we could make the concl
usion that whether the value of a firm in the captial market is undervalued or not. On
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1978 年至 2008 年，历经 30 年改革大潮洗礼的中国医药行业发生了翻天覆地、
日新月异的变化。30 年来，中国医药工业增长速度一直高于国内生产总值
（GDP）。从 1978 年到 2007 年，医药工业产值年均递增 16.8%，成为国民经济
中发展 快的行业之一。 
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